https://mindmedicinelaw.com/briefing/trump-s-executive-order-accelerates-psychedelic-therapies-20260629-17633The Psychedelic Journalen2026-06-29T15:05:06.663131+00:00Trump's Executive Order Accelerates Psychedelic Therapiespsychedelic therapies, executive order, Trump, FDA, clinical trials, market access, investor confidence, regulatory risks, mental health, Compass Pathwayshttps://mindmedicinelaw.com/briefing/microdosing-psychedelics-mood-and-cognition-insights-20260628-17616The Psychedelic Journalen2026-06-29T15:06:30.935489+00:00Microdosing Psychedelics: Mood and Cognition Insightspsychedelic microdosing, mood enhancement, cognitive function, serotonin receptors, neuroplasticity, clinical trials, mental health treatment, regulatory frameworks, long-term effects, self-medication riskshttps://mindmedicinelaw.com/briefing/quantifying-psychedelic-experiences-new-frameworks-and-challenges-20260628-17552The Psychedelic Journalen2026-06-29T15:06:12.133391+00:00Quantifying Psychedelic Experiences: New Frameworks and Challengespsychedelic research, computational framework, large language models, subjective experiences, ethical concerns, mystical experiences, phenomenology, demographic bias, mystical-score saturation, neurosciencehttps://mindmedicinelaw.com/briefing/kolmogorov-theory-framework-in-psychedelic-research-20260628-17555The Psychedelic Journalen2026-06-29T15:06:00.811717+00:00Kolmogorov-Theory Framework in Psychedelic ResearchKolmogorov-Theory framework, psychedelic research, subjective experiences, large language models, mental health, demographic bias, epistemological challenges, computational phenomenologyhttps://mindmedicinelaw.com/briefing/kolmogorov-theory-s-role-in-neuropsychiatry-and-psychedelics-20260628-17557The Psychedelic Journalen2026-06-29T15:05:36.833529+00:00Kolmogorov Theory's Role in Neuropsychiatry and Psychedelicskolmogorov theory, neuropsychiatry, computational neuroscience, personalized brain stimulation, psychedelic research, neurotwin technology, clinical trials, consciousness, emotional states, brain stimulation therapieshttps://mindmedicinelaw.com/briefing/microdosing-psychedelics-cognitive-impairment-and-mood-myths-20260628-17558The Psychedelic Journalen2026-06-29T15:05:21.175233+00:00Microdosing Psychedelics: Cognitive Impairment and Mood Mythspsychedelic microdosing, cognitive impairment, mood benefits, LSD, psilocybin, expectancy bias, clinical trials, cardiovascular risks, 5-HT 2 B receptor, placebo-controlledhttps://mindmedicinelaw.com/briefing/psilocybin-s-role-in-fear-memory-and-neuroplasticity-implications-20260628-17469The Psychedelic Journalen2026-06-28T22:04:05.155593+00:00Psilocybin's Role in Fear Memory and Neuroplasticity: Implicationspsilocybin, fear memory, neuroplasticity, PTSD treatment, psychedelic research, mental health, serotonin receptors, clinical trials, policy implications, brain regionshttps://mindmedicinelaw.com/briefing/party-drug-shows-promise-for-resistant-depression-treatment-20260628-17317The Psychedelic Journalen2026-06-28T15:04:24.344468+00:00Party Drug Shows Promise for Resistant Depression Treatmentresistant depression, recreational drug, mental health treatment, psychedelic research, clinical trials, neurotransmitter systems, regulatory challenges, treatment options, suicidal thoughts, drug efficacyhttps://mindmedicinelaw.com/briefing/psilocybin-nears-fda-approval-impact-on-therapy-and-market-20260628-17316The Psychedelic Journalen2026-06-28T15:04:08.088647+00:00Psilocybin Nears FDA Approval: Impact on Therapy and Marketpsilocybin, FDA approval, psychedelic therapy, mental health treatment, clinical trials, market dynamics, regulatory frameworks, psychedelic research, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/vortioxetine-s-potential-in-alzheimer-s-preclinical-insights-20260626-17252The Psychedelic Journalen2026-06-28T15:04:33.936470+00:00Vortioxetine's Potential in Alzheimer's: Preclinical Insightsvortioxetine, Alzheimer's disease, cognitive function, rat model, clinical trials, neuroprotection, Amyloid-β1–42, neuroscience, preclinical study, neurodegenerationhttps://mindmedicinelaw.com/briefing/psychosocial-protocols-in-psychedelic-therapy-a-scoping-review-20260626-17205The Psychedelic Journalen2026-06-28T15:04:16.104466+00:00Psychosocial Protocols in Psychedelic Therapy: A Scoping Reviewpsychedelic therapy, psychosocial protocols, standardization, mental health, research transparency, cultural responsiveness, clinical trials, psychedelic substances, therapy evaluation, interdisciplinary researchhttps://mindmedicinelaw.com/briefing/propofol-ketamine-neuroprotective-effects-in-oxidative-stress-20260618-16257The Psychedelic Journalen2026-06-27T22:04:08.668942+00:00Propofol & Ketamine: Neuroprotective Effects in Oxidative Stresspropofol, ketamine, oxidative stress, neuroprotection, A549 cells, clinical research, neurodegenerative diseases, antioxidant defense, psychedelic research, therapeutic strategieshttps://mindmedicinelaw.com/briefing/music-s-role-in-psychedelic-therapy-trials-a-review-20260615-15139The Psychedelic Journalen2026-06-27T22:04:31.532394+00:00Music's Role in Psychedelic Therapy Trials: A Reviewpsychedelic therapy, clinical trials, music playlists, psychotherapy, treatment efficacy, standardized guidelines, patient experience, therapeutic outcomes, neuroscience, policy implicationshttps://mindmedicinelaw.com/briefing/ketamine-s-role-as-an-antidepressant-clinical-insights-20260615-15470The Psychedelic Journalen2026-06-27T22:04:20.704975+00:00Ketamine's Role as an Antidepressant: Clinical Insightsketamine, antidepressant, clinical trials, mental health, NMDA receptors, treatment-resistant depression, psychiatry, neuroscience, FDA approval, mental health policyhttps://mindmedicinelaw.com/briefing/berberine-s-potential-in-multiple-sclerosis-therapy-20260614-15092The Psychedelic Journalen2026-06-27T22:04:51.558597+00:00Berberine's Potential in Multiple Sclerosis Therapyberberine, multiple sclerosis, clinical trials, immunomodulatory, neuroprotective, bioavailability, nanoformulations, JAK/STAT pathway, SPHK1/S1P pathwayhttps://mindmedicinelaw.com/briefing/designer-drugs-nps-chemistry-and-forensic-challenges-20260614-14590The Psychedelic Journalen2026-06-27T22:04:41.572239+00:00Designer Drugs & NPS: Chemistry and Forensic Challengesdesigner drugs, novel psychoactive substances, forensic challenges, public health, regulatory changes, analytical techniques, AI-assisted forensic, drug abuse trends, toxicological effects, global patternshttps://mindmedicinelaw.com/briefing/patient-driven-care-in-psychedelic-therapy-implications-and-challenges-20260613-15138The Psychedelic Journalen2026-06-27T22:05:03.156838+00:00Patient-Driven Care in Psychedelic Therapy: Implications and Challengespatient-driven care, psychedelic therapy, patient autonomy, personalized treatment, therapeutic outcomes, clinical trials, public health, ethics in therapy, standardized protocols, policy implications